Israeli infant receives first gene therapy for rare genetic epilepsy, marking medical milestone
A 10-month-old infant in Israel became the first patient to receive gene therapy for a rare form of epilepsy, according to a report from Sheba Medical Center. The treatment, which delivered a functional copy of the SCN1A gene directly into the brain, targeting a genetic mutation linked to Dravet syndrome, was described as “a groundbreaking advancement” by the hospital’s neurology team.
How the therapy works
The intervention involved a viral vector to introduce a corrected SCN1A gene into the infant’s central nervous system. Dravet syndrome, a severe epilepsy disorder caused by mutations in the SCN1A gene, typically leads to frequent, difficult-to-control seizures and developmental delays. The therapy aims to restore normal neuronal function by addressing the root genetic cause, rather than just managing symptoms.
Significance of the treatment
This marks the first time a gene therapy has been administered directly to an infant’s brain for a genetic epilepsy disorder, according to the medical team at Sheba Medical Center. “This approach could redefine treatment paradigms for genetic neurological conditions,” said Dr. Rachel Ben-Yosef, a pediatric neurologist involved in the case. The procedure was conducted in collaboration with researchers from the Weizmann Institute of Science, who provided preclinical data on the therapy’s safety and efficacy.
Early outcomes and next steps
The infant showed improved seizure control within weeks of the treatment, though long-term results are still under observation. The case has drawn attention from global medical communities, with the European Medicines Agency and U.S. Food and Drug Administration both expressing interest in the therapy’s potential. Clinical trials for broader applications are expected to begin in 2024, pending regulatory approvals.
Why this matters
Gene therapies for neurological disorders remain rare due to challenges in delivering genetic material to the brain. This treatment’s success could pave the way for similar approaches to other genetic conditions, such as spinal muscular atrophy or certain types of autism. “This is a critical step toward precision medicine for inherited diseases,” said Dr. Michael Goldberg, a geneticist at the University of Tel Aviv.
Comparison with prior treatments
Traditional therapies for Dravet syndrome focus on anticonvulsant medications, which often fail to fully control seizures. In contrast, gene therapy targets the underlying genetic defect, offering a potential cure rather than symptom management. While no direct comparisons exist for brain-targeted gene therapies in infants, animal studies suggest this approach may reduce seizure frequency by up to 70%.
Future implications
The treatment’s success has sparked discussions about expanding gene therapy to other genetic disorders. However, experts caution that risks, including immune responses to viral vectors, must be carefully managed. “This is a promising start, but we need more data before it becomes standard care,” said Dr. Sarah Cohen, a neurologist at Hadassah Medical Center.
Key takeaways
- The first gene therapy for a rare genetic epilepsy was administered to an Israeli infant in 2023.
- The treatment uses a viral vector to deliver a functional SCN1A gene to the brain.
- Early results show improved seizure control, with clinical trials planned for 2024.
- The approach could influence future treatments for other genetic neurological conditions.